How are CAR-T and monoclonals reshaping the ALL treatment landscape?
Recent high-profile approvals for the CAR-T therapy Kymriah, and monoclonal antibodies Blincyto and Besponsa have reignited interest in ALL. Do these therapies live up to the hype in terms of their current impact and future potential? With further CAR-T therapies in the pipeline, how will the future of this class evolve and could the allogeneic CAR-T product UCART19 provide an ‘off the shelf’ solution? TKIs have improved the prognosis for Ph-positive ALL, but how do oncologists choose between these drugs, and how could their use develop? Could ruxolitinib or currently approved TKIs make their mark in Ph-like ALL? Furthermore, the experts discuss whether the success of venetoclax in CLL and AML could be replicated in ALL.
In this report, you’ll learn about these issues and more, as 12 of the world’s leading KOLs offer candid insights on seven marketed therapies and seven pipeline drugs.
Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!
“I think blinatumomab and inotuzumab will show efficacy in the upfront setting. The next step will be to see if they can replace phases of chemotherapy. I think CAR-T cell therapy is going to move to the upfront setting for certain patients. Overall, immunotherapies will be more prominent in the relapsed setting and start to move upfront.”
US Key Opinion Leader
“We’re going to see improved survival in adults like we’ve seen in children over the past several decades. Most adults are going to be cured of ALL. We’ll use a combination of these drugs. We’ll start them individually, but we’re going to be using a lot of cocktails and sequencing.”
US Key Opinion Leader
“ALL therapy is witnessing a renaissance. This is a time for great excitement, starting with blinatumomab, which is activating the host T-cells, and with CAR-T.”
EU Key Opinion Leader
Marketed therapies
Phase III
Phase I/II
KOLs from North America
KOLs from Europe
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved